https://www.selleckchem.com/pr....oducts/sirpiglenasta
holds the promise for the development of programs that are practical, scalable, and can be implemented in most clinical sites within the foreseeable future. Pseudomonas aeruginosa is one of the most feared nosocomial pathogens. Treatment of P. aeruginosa infections is challenging because of the limited choices of antibiotics and the emergent resistance of the pathogen. The present review aims at addressing the management of P. aeruginosa infections and highlighting the novel antibiotics that show a future promising role. Novel fl
Like
Comment
Share
